Catherine Labbé

3.1k total citations
71 papers, 1.4k citations indexed

About

Catherine Labbé is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Catherine Labbé has authored 71 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 14 papers in Neurology. Recurrent topics in Catherine Labbé's work include Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Lung Cancer Research Studies (13 papers). Catherine Labbé is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Lung Cancer Research Studies (13 papers). Catherine Labbé collaborates with scholars based in Canada, United States and France. Catherine Labbé's co-authors include Natasha B. Leighl, John D. Rioux, Kevin Jao, Pascale Tomasini, Owen A. Ross, Frances A. Shepherd, Philippe Goyette, Geoffrey Liu, Ramnik J. Xavier and Gérard Maisse and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Catherine Labbé

69 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine Labbé Canada 21 537 515 332 230 189 71 1.4k
Éric Tabone France 26 368 0.7× 303 0.6× 711 2.1× 98 0.4× 202 1.1× 57 1.7k
Ken Op de Beeck Belgium 29 738 1.4× 430 0.8× 1.1k 3.4× 126 0.5× 72 0.4× 77 2.2k
Jonas Sjölund Sweden 18 331 0.6× 219 0.4× 887 2.7× 120 0.5× 95 0.5× 29 1.3k
Georgia Levidou Greece 25 377 0.7× 294 0.6× 823 2.5× 82 0.4× 80 0.4× 92 1.8k
Zachary T. Herbert United States 14 451 0.8× 289 0.6× 722 2.2× 44 0.2× 174 0.9× 25 1.4k
Sara M. Camp United States 23 102 0.2× 329 0.6× 769 2.3× 176 0.8× 169 0.9× 63 1.8k
Masanori Naito Japan 19 413 0.8× 205 0.4× 693 2.1× 77 0.3× 129 0.7× 55 1.7k
Francesc Alameda Spain 26 371 0.7× 180 0.3× 780 2.3× 50 0.2× 104 0.6× 78 1.7k
Hiroki Odagiri Japan 16 393 0.7× 152 0.3× 713 2.1× 68 0.3× 192 1.0× 36 1.3k
Selen C. Muratoglu United States 21 244 0.5× 231 0.4× 848 2.6× 38 0.2× 173 0.9× 33 1.5k

Countries citing papers authored by Catherine Labbé

Since Specialization
Citations

This map shows the geographic impact of Catherine Labbé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Labbé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Labbé more than expected).

Fields of papers citing papers by Catherine Labbé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Labbé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Labbé. The network helps show where Catherine Labbé may publish in the future.

Co-authorship network of co-authors of Catherine Labbé

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Labbé. A scholar is included among the top collaborators of Catherine Labbé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Labbé. Catherine Labbé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blais, Normand, Catherine Labbé, Louis Gaboury, et al.. (2024). A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.. Journal of Clinical Oncology. 42(16_suppl). 8577–8577. 1 indexed citations
2.
Desmeules, Patrice, et al.. (2023). Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. Current Oncology. 30(1). 575–585. 5 indexed citations
3.
Patel, Munjal, et al.. (2023). P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis. Journal of Thoracic Oncology. 18(11). S381–S381. 1 indexed citations
4.
Li, Zhonglin, Nathalie Gaudreault, Cyndi Henry, et al.. (2022). Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers. Cancer Epidemiology Biomarkers & Prevention. 31(12). 2219–2227. 6 indexed citations
5.
Ugalde, Paula A., et al.. (2022). Transthoracic needle biopsy versus surgical diagnosis for solid pulmonary nodules. Journal of Thoracic Disease. 14(7). 2472–2480. 3 indexed citations
6.
7.
Heckman, Michael G., Catherine Labbé, Ana Kolicheski, et al.. (2021). Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease. Parkinsonism & Related Disorders. 83. 22–30. 5 indexed citations
8.
Noisel, Nolwenn, et al.. (2021). Epidemiological characteristics of the COVID-19 spring outbreak in Quebec, Canada: a population-based study. BMC Infectious Diseases. 21(1). 435–435. 5 indexed citations
9.
Payette, Yves, et al.. (2021). Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort. BMJ Open. 11(4). e045078–e045078. 6 indexed citations
10.
11.
Rousseau, Caroline, David M. Goldenberg, Ludovic Ferrer, et al.. (2020). Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Nuclear Medicine. 61(8). 1205–1211. 28 indexed citations
12.
Gaudreault, Nathalie, Cyndi Henry, Paula A. Ugalde, et al.. (2018). Tumor-based gene expression biomarkers to predict survival following curative intent resection for stage I lung adenocarcinoma. PLoS ONE. 13(11). e0207513–e0207513. 2 indexed citations
13.
Hueniken, Katrina, M. Catherine Brown, Liang Mao, et al.. (2018). MA18.09 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 13(10). S420–S421. 1 indexed citations
14.
Hueniken, Katrina, Catherine Labbé, M. Catherine Brown, et al.. (2018). P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment. Journal of Thoracic Oncology. 13(10). S586–S586. 1 indexed citations
15.
Sung, Max W., Alona Zer, Leila Khoja, et al.. (2018). P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S929–S929. 1 indexed citations
16.
Labbé, Catherine, Michaela R. Anderson, Serge Simard, et al.. (2017). Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience. Current Oncology. 24(6). 367–373. 21 indexed citations
17.
Doherty, Mark, Grzegorz Korpanty, Pascale Tomasini, et al.. (2017). Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. Radiotherapy and Oncology. 123(2). 195–202. 40 indexed citations
18.
Tomasini, Pascale, et al.. (2016). Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. The Oncologist. 21(12). 1450–1460. 96 indexed citations
19.
Labbé, Catherine, et al.. (2016). Wait times for diagnosis and treatment of lung cancer: a single centre experience. Annals of Oncology. 27. vi523–vi523. 4 indexed citations
20.
Jao, Kevin, Catherine Labbé, & Natasha B. Leighl. (2015). Ready or Not? Lung Cancer Diagnosis in 2015. Current Oncology. 22(4). 239–242. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Tabone Breakdown of academic impact, for papers by Ken Op de Beeck Breakdown of academic impact, for papers by Jonas Sjölund Breakdown of academic impact, for papers by Georgia Levidou Breakdown of academic impact, for papers by Zachary T. Herbert Breakdown of academic impact, for papers by Sara M. Camp Breakdown of academic impact, for papers by Masanori Naito Breakdown of academic impact, for papers by Francesc Alameda Breakdown of academic impact, for papers by Hiroki Odagiri Breakdown of academic impact, for papers by Selen C. Muratoglu
Rankless by CCL
2026